Prochlorperazine Edisylate Injection

[27 February 2015]

Products Affected - Description

Prochlorperazine injection 5 mg/mL, Ben Venue (formerly Bedford product)
2 mL vial, 10 count (NDC 55390-0077-10)
10 mL vial (NDC 55390-0077-01)

Prochlorperazine injection 5 mg/mL, Heritage Pharmaceuticals
2 mL vial, 10 count (NDC 23155-0294-42)

Reason for the Shortage

  • Ben Venue stopped production in its plant in Bedford, Ohio and closed in July 2014.
  • Heritage Pharmaceuticals could not provide a reason for the shortage.

Available Products

There are no presentations available.

Estimated Resupply Dates

Heritage has prochlorperazine injection on back order and the company cannot estimate a release date.

Related Shortages


February 27, 2015, University of Utah, Drug Information Service. Copyright 2015, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.